Rachel A. Burga

Pliant (United States) — United States

Medicine · Health Sciences

20h-index1.8kcitations71works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(41), Immune Cell Function and Interaction(24), Immunotherapy and Immune Responses(19), Cancer Immunotherapy and Biomarkers(10), Neuroblastoma Research and Treatments(9)

Publications71 total

Potent cytotoxic tumor-infiltrating lymphocytes can be generated from immune-excluded chondrosarcomas using regulatable membrane-bound IL15
Cancer Immunology Research·2026Open Access
1655P Translational data validate OBX-115 mechanism of action: Impact of dosing on clinical outcome in advanced (adv) melanoma
Annals of Oncology·2025
OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma.
Journal of Clinical Oncology·2025
IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15
Molecular Therapy·2025· 5 citedOpen Access
Abstract B001: Effective generation of potent tumor-infiltrating lymphocytes (TIL) expressing regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) from immune-excluded chondrosarcoma
Cancer Immunology Research·2025
Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation
Cytotherapy·2024· 4 cited
162 TCR repertoire profiling for FFPE RNA and DNA samples from chondrosarcoma reveals the presence of tumor-enriched invariant T cells
Regular and Young Investigator Award Abstracts·2024Open Access
444 Potential feasibility of core needle biopsy tumor tissue procurement method for TIL cell therapy with OBX-115 in non-small cell lung cancer (NSCLC)
Regular and Young Investigator Award Abstracts·2024Open Access
Abstract LB072: Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans
Cancer Research·2024· 1 cited
348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA
Regular and Young Investigator Award Abstracts·2023Open Access
Abstract LB096: IL15-engineered tumor infiltrating lymphocytes (cytoTIL15TM) exhibit activity against autologous tumor cells from multiple solid tumor indications without IL2
Cancer Research·2023· 4 cited
Abstract LB093: Engineering tumor infiltrating lymphocytes from sarcoma and colorectal tumors with membrane bound IL-15 for IL-2 independent expansion and enhanced cytotoxicity against autologous tumor cell lines
Cancer Research·2023
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
2023Open Access
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Supplementary Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
2023Open Access
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Rohan Fernandes(15), Steven C. Katz(13), Catherine M. Bollard(13), Carolina Colli Cruz(13), N. Joseph Espat(12), Richard P. Junghans(12), Mitchell Thorn(11), Michelle Ols(9), Jan ter Meulen(9), Eric Yvon(8), Gary R. Point(7), Cang T. Nguyen(7), Lauren A. Licata(7), Jeremy H. Tchaicha(7), Alonso Villasmil Ocando(7), Elise McCormack(6), Pranay D. Khare(6), Brian F. Stainken(6), Earle O. Assanah(6), Allison B. Powell(6)